Preclinical Study Validates Science Behind AlloSource AlloStem Cellular Bone Allograft

By Julie A. Vetalice

Preclinical data on adipose-derived mesenchymal stem cells in a rat model, using technology similar to AlloSource's AlloStem® Cellular Bone Allograft process, showed bone formation within a critical-sized defect in all study subjects. Stem cells were detected for up to 84 days in areas of new formation, and differentiated within the bony repair tissue.

AlloStem comprises partially demineralized allograft bone + adipose-derived mesenchymal stem cells, designed to support bone formation through osteoconduction, osteoinduction and osteogenesis. The company received a U.S. patent for the product in 4Q15.

Sources: AlloSource, ORTHOWORLD Inc.

Orthobiologics and stem cells are emerging as a potential treatment option as surgeons find new ways to treat challenging cases by augmenting the body’s natural healing process. However, there is mixed feedback on the use of orthobiologics in the segment, as shared in the ORTHOPRENEUR article, "Arthroscopy/Soft Tissue Companies Address Knee, Shoulder Repair" from April 2016.

Product Labels: Bone Graft Materials/DBM

Tags: Trial/Study